Opinion|Videos|January 4, 2024
The Future of Metastatic and Unresectable Melanoma Treatment
The panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.
Advertisement
Advertisement
Related to this article
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
Advertisement
Advertisement
Trending on OncLive
1
QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC
2
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
3
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
4
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
5